{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:01:22Z","timestamp":1794650482721,"version":"4.9.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0140136","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T20:29:22Z","timestamp":1444768162000},"page":"e0140136","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity"],"prefix":"10.1371","volume":"10","author":[{"given":"N\u00f3ra","family":"Kutszegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes F.","family":"Semsei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"G\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit C.","family":"S\u00e1gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Csord\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Lautner-Csorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina M\u00edta","family":"G\u00e1bor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor T.","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel J.","family":"Erd\u00e9lyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Szalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1556\/OH.2014.29918","article-title":"Importance of the National Childhood Cancer Registry in the field of paediatric oncology care in Hungary","volume":"155","author":"M Garami","year":"2014","journal-title":"Orv Hetil"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(04)17550-8","article-title":"Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study","volume":"364","author":"E Steliarova-Foucher","year":"2004","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":"Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002","volume":"32","author":"J Stary","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1182\/blood-2009-03-210906","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 (vol 111, pg 4477, 2008)","volume":"113","author":"A Moricke","year":"2009","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4137\/CMO.S10242","article-title":"Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia","volume":"8","author":"AF Andrade","year":"2014","journal-title":"Clin Med Insights Oncol"},{"key":"ref6","first-page":"241","article-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","volume":"1","author":"VI Avramis","year":"2006","journal-title":"Int J Nanomedicine"},{"issue":"Suppl","key":"ref7","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.clml.2014.06.017","article-title":"Asparaginase in acute lymphoblastic leukemia","volume":"14","author":"JD Kawedia","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"R Pieters","year":"2011","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"A Pession","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"ref10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835d7d85","article-title":"Optimizing asparaginase therapy for acute lymphoblastic leukemia","volume":"25","author":"C Rizzari","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"MH Woo","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"HJ Muller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.critrevonc.2006.07.009","article-title":"Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia","volume":"61","author":"UK Narta","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1043454212471728","article-title":"Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults","volume":"30","author":"SE Shinnick","year":"2013","journal-title":"J Pediatr Oncol Nurs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/clpt.2010.94","article-title":"Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity","volume":"88","author":"SH Chen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","first-page":"1","article-title":"Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia","author":"V Rajic","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.tpj.6500480","article-title":"Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy","volume":"8","author":"DJ Erdelyi","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"ref18","article-title":"In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia","author":"A Gezsi","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.psychres.2012.03.048","article-title":"Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction","volume":"199","author":"JR Bishop","year":"2012","journal-title":"Psychiatry Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajmg.b.30294","article-title":"Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample","volume":"141B","author":"C Magri","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate\u2014a Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Y Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society Series B-Methodological"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A direct approach to false discovery rates","volume":"64","author":"JD Storey","year":"2002","journal-title":"Journal of the Royal Statistical Society Series B-Statistical Methodology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/pr.110.003533","article-title":"Pharmacogenetics, pharmacogenomics, and individualized medicine","volume":"63","author":"Q Ma","year":"2011","journal-title":"Pharmacol Rev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/sj.bjp.0704134","article-title":"Characterization of ionotropic glutamate receptors in human lymphocytes","volume":"133","author":"G Lombardi","year":"2001","journal-title":"Br J Pharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.4049\/jimmunol.170.8.4362","article-title":"Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration","volume":"170","author":"Y Ganor","year":"2003","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00702-014-1167-5","article-title":"The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells","volume":"121","author":"Y Ganor","year":"2014","journal-title":"J Neural Transm"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.4049\/jimmunol.177.10.6695","article-title":"Glutamate released by dendritic cells as a novel modulator of T cell activation","volume":"177","author":"R Pacheco","year":"2006","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial","volume":"112","author":"R Pieters","year":"2008","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"10270","DOI":"10.1073\/pnas.91.22.10270","article-title":"Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence","volume":"91","author":"J Egebjerg","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrg1327","article-title":"Genomic variants in exons and introns: identifying the splicing spoilers","volume":"5","author":"F Pagani","year":"2004","journal-title":"Nat Rev Genet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.mcna.2010.03.002","article-title":"The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization","volume":"94","author":"M Pagani","year":"2010","journal-title":"Med Clin North Am"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2015-02-628800","article-title":"Genome-wide analysis links NFATC2 with asparaginase hypersensitivity","volume":"126","author":"CA Fernandez","year":"2015","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0140136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:35:52Z","timestamp":1718134552000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0140136"}},"subtitle":[],"editor":[{"given":"Obul Reddy","family":"Bandapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0140136","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.t003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.t004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.t005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.t006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0140136.s004","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}